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With the large number of promising new molecules that
are currently available for clinical testing, clinical trials
need to detect a drug’s benefit (or harm) as quickly as
possible. In parallel with the need for speed in clinical
development, advances in molecular biology, high
throughput technologies and imaging techniques provide
investigators with an ever growing number of biomarkers
which can be used for a variety of purposes: to inform go
/ no go decisions in early clinical development, to stratify
patients, to target subsets, to adjust therapy, or to replace
clinical endpoints in the comparison of the new drug
with standard treatments. This talk will focus on the lat-
ter goal, and will discuss the type of statistical evidence
required for a biomarker (or a clinical endpoint) to be an
acceptable outcome measure for use in clinical trials [1].
Historically, the first formal definition of surrogacy is
due to Prentice [2]. While this definition has had a huge
role in focusing attention on the need for formal statisti-
cal criteria to validate a potential surrogate, it may also
have led to excessively pessimistic views about the
potential for any outcome measure (whether it be a clin-
ical endpoint or a biomarker) to ever qualify as a good
(let alone “perfect”) surrogate. A large amount of
research has been devoted to operational criteria to
implement Prentice’s definition in practice.
An even larger amount of research has been devoted
to a different approach based on statistical associations
between the endpoints (surrogate and true), and
between treatment effects on these endpoint. It has
been proposed that a good surrogate must be tightly
correlated with the true endpoint (the so-called “indivi-
dual-level” association), and that the treatment effect on
the surrogate must be tightly correlated with the treat-
ment effect on the true endpoint (the so-called “trial-
level” association) [3]. Showing that both criteria are
met usually requires a meta-analysis of randomized
trials, or one large trials that can be broken down in
smaller units (such as participating countries). When
such data are available, the predictive value of potential
surrogate biomarkers can be investigated, and the “sur-
rogate threshold effect” can be estimated as the mini-
mum effect on the surrogate biomarker that predicts a
statistically significant effect on the clinical endpoint [4].
A very different line of research has evolved from con-
cepts of causal inference, in particular the concept of
“principal stratification”, in which treatment effects on
the true endpoint are estimated within strata defined by
different surrogate values [5]. The conceptual elegance
of this approach has not yet led to convincing applica-
tions, in large part because it has proven challenging to
find good estimation methods for the counterfactual
probabilities that are required to validate a surrogate [6].
It is likely, however, that causal inference will play a key
role in future attempts to validate surrogate endpoints.
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